LLLT Combined With CDT in Breast Cancer-Related Lymphedema

This study is currently recruiting participants.
Verified November 2013 by New York University School of Medicine
Sponsor:
Collaborator:
Hunter College
Information provided by (Responsible Party):
Tara Denham, New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT01351376
First received: May 9, 2011
Last updated: November 7, 2013
Last verified: November 2013

May 9, 2011
November 7, 2013
May 2011
May 2015   (final data collection date for primary outcome measure)
Arm Volume [ Time Frame: 5-6 measurements over the course of 13-14 months ] [ Designated as safety issue: No ]
Circumferential measurements [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
The measurements will be conducted on both affected and non-affected limbs at the hand proximal to the metacarpals, wrist, and then every 4 cm from the wrist to axilla.
Complete list of historical versions of study NCT01351376 on ClinicalTrials.gov Archive Site
Quality of Life [ Time Frame: 5-6 measurements over a course of 12-13 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study

This study aims to explore the effects of Low Level Laser Therapy (LLLT) on breast cancer-related lymphedema when utilized in conjunction with Complex Decongestive Therapy (CDT) when compared to CDT treatment alone. The investigators hypothesize that the addition of LLLT to CDT will result in statistically significant improvements and greater long-term benefits as measured by changes in arm volume and girth, pain levels, tissue texture, symptoms experienced, and quality of life when compared to the benefits of CDT alone for the treatment of breast cancer-related lymphedema.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Breast Cancer
  • Lymphedema
  • Device: Low Level Laser Therapy
    Placebo LLL combined with CDT
    Other Names:
    • Low Level Laser
    • Complex Decongestive Therapy
  • Device: Low Level Laser
    Active LLL combined with CDT
    Other Names:
    • Low Level Laser
    • Complex Decongestive Therapy
  • Placebo Comparator: Placebo
    CDT + inactive LLL
    Intervention: Device: Low Level Laser Therapy
  • Active Comparator: LLL combined with CDT
    CDT + active LLL
    Intervention: Device: Low Level Laser
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
May 2015
May 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection)
  • stage II or III unilateral secondary upper extremity lymphedema (as defined by the International Society of Lymphology)
  • girth ≥ 2 cm circumferential difference and/or volume ≥ 200 mL compared to the uninvolved upper extremity at any 4 cm segment
  • able to commit to a long term follow-up schedule

Exclusion Criteria:

  • active cancer/metastatic cancer
  • currently receiving or have plans for adjuvant radiation or chemotherapy
  • pregnant
  • presence of other extremity lymphedema (primary or secondary)
  • pacemaker
  • artificial joints in the upper quadrants
  • renal failure
  • arterial insufficiency
  • congestive heart failure
  • chronic inflammatory conditions
  • history of deep vein thrombosis (DVT) in the lymphedematous upper extremity
  • previous treatment with Low Level Laser (regardless of indication)
  • medication(s) known to affect body fluid balance
  • body mass index (BMI) > 40 (morbid obesity)
Female
21 Years and older
No
Contact: Teresa Denham, PT, MA 212-263-8466 tara.denham@nyumc.org
United States
 
NCT01351376
10-00923
No
Tara Denham, New York University School of Medicine
New York University School of Medicine
Hunter College
Principal Investigator: Teresa Denham, PT, MA NYU Rusk Institute of Rehabilitation Medicine
New York University School of Medicine
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP